Cambrex has posted a positive set of Q2 results, recording an operating income of $9m (€6.3m), but warned that the second half of the year is likely to be down on the corresponding six months of last year.
Cambrex Corp, the US-based manufacturer of small-molecule active
pharmaceutical ingredients (APIs) and advanced intermediates for
the drug industry, has announced that one of its customers is
recalling a product for which Cambrex...
Life sciences firm Cambrex has reported a $140.3m (€116.7m) loss in
Q4 as opposed to a profit of $4.9m in Q4 last year, hit by lower
long-term profitability projections for its Biopharma unit, as
biotech companies seem to lose their...